熱門資訊> 正文
由于第二季度财报发布后持续低迷，DexCom下跌6%
2025-08-26 02:20
- 德康醫療(DXCM) 0
- 纳比特(NA) 0
- 盛大科技(SDA) 0
- DexCom (NASDAQ:DXCM) is down ~6% in Monday trading, continuing a downward trend that began in late July following the release of its Q2 financial results.
- While there doesn't appear to be a clear catalyst for today's decline, DexCom was trading above $89 per share just before the July 30 earnings release. On Monday, the price dropped to as low as $77.10 per share.
- While DexCom's Q2 results beat on both lines and it raised its 2025 revenue guidance, the stock fell after the closing bell on July 30.
- The maker of continuous glucose monitors did report that its non-GAAP gross margin fell to 60.1% from 63.5% in the year-ago period.
- A look at insider transactions finds that over the last six months, there have been net share purchases (accounting for shares sold) of ~316K shares.
More on DexCom
- DexCom, Inc. 2025 Q2 - Results - Earnings Call Presentation
- DexCom, Inc. (DXCM) Q2 2025 Earnings Call Transcript
- DexCom: Delivering Consistent Growth
- DexCom raises 2025 revenue guidance to $4.625B as type 2 non-insulin access expands
- DexCom falls despite results beat, revenue outlook raise
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
